European Lung Cancer Congress 2023

Jordi Remon-Masip (Department of Cancer Medicine, Gustave Roussy, Villejuif, France) and colleagues investigated a sequential treatment approach of gefitinib followed by osimertinib versus osimertinib upfront in patients with advanced EGFR-mutant resectable non-small-cell lung cancer (NSCLC) in the phase 2 APPLE trial. Remon-Masip presented the final overall survival findings and exploratory analyses.